DANAHER CORP (DHR) 263.79 -6.06 (-2.25%)
263.79 -6.06 (-2.25%)
US2358511028 - Common Stock
Fundamental Rating
Taking everything into account, DHR scores 4 out of 10 in our fundamental rating. DHR was compared to 66 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of DHR get a neutral evaluation. Nothing too spectacular is happening here. DHR is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
DHR has a Profit Margin of 22.57%. This is better than the industry average of 16.49%.
The Piotroski-F score of DHR is 7.00. This is a strong score and indicates good health and profitability for DHR.
DHR's Return On Assets of 8.42% is in line with the rest of the industry. The industry average Return On Assets is 8.42%.
DHR's Return On Equity of 14.18% is worse than the rest of the industry. The industry average Return On Equity is 16.61%.
VS Industry
ROA (8.42%) VS Industry: 52% outperformed.
0.30
57.39
ROE (14.18%) VS Industry: 36% outperformed.
1.18
180.91
Profit Margin (22.57%) VS Industry: 78% outperformed.
0.20
383.95
Valuation
Valuation Rating
With a Price/Earnings Ratio of 24.09, DHR is valued on the expensive side.
Compared to an average industry Price/Earning Ratio of 28.56, DHR is valued in line with its industry peers.
The PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
With a price book ratio of 3.83, DHR is valued correctly.
When comparing the Enterprise Value to EBITDA ratio of DHR to the average industry ratio of 20.72, DHR is valued in line with its industry peers.
With a Forward Price/Earnings Ratio of 25.03, DHR is valued very expensively.
When comparing the price book ratio of DHR to the average industry price book ratio of 2.61, DHR is valued more expensive than its industry peers.
VS Industry
Price/Earnings (24.09) VS Industry: 57% outperformed.
122.09
7.53
Price/Book (3.83) VS Industry: 37% outperformed.
52.24
0.33
Enterprise Value/ EBITDA (19.26) VS Industry: 60% outperformed.
746.65
2.30
Growth
Growth Rating
DHR shows a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 22.13% yearly.
DHR shows quite a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 15.19% yearly.
DHR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 8.85%.
DHR is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 8.60% yearly.
Looking at the last year, DHR shows a small growth in Revenue. The Revenue has grown by 6.85% in the last year.
DHR is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 5.95% yearly.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 22.13% | 32.57% | 8.85% | -3.77% | 2.85% | 5.28% | 8.6% |
| Revenue | 15.19% | 20.67% | 6.85% | -0.07% | 3.83% | 5.18% | 5.95% |
Health
Health Rating
An Altman-Z score of 4.91 indicates that DHR is not in any danger for bankruptcy at the moment.
The Altman-Z score of DHR is much better than the industry average of 2.40.
The Piotroski-F score of DHR is 7.00. This is a strong score and indicates good health and profitability for DHR.
DHR has a Current Ratio of 1.89. This is a normal value and indicates that DHR is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.52 indicates that DHR should not have too much problems paying its short term obligations.
Compared to an average industry Current Ratio of 4.77, DHR is worse placed to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of DHR to the average industry Current Ratio of 4.30, DHR is less able to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.08, DHR is more dependent on financing than its industry peers.
VS Industry
Debt/Equity (0.38) VS Industry: 36% outperformed.
3.88
0.00
Quick Ratio (1.52) VS Industry: 30% outperformed.
0.04
40.60
Current Ratio (1.89) VS Industry: 24% outperformed.
0.04
40.60
Altman-Z (4.91) VS Industry: 66% outperformed.
-152.43
23.82
Dividend
Dividend Rating
On average, the dividend of DHR grows each year by 9.32%, which is quite nice.
DHR pays out 11.52% of its income as dividend. This is a sustainable payout ratio.
DHR has been paying a dividend for at least 10 years, so it has a reliable track record.
Compared to an average industry Dividend Yield of 0.36, DHR has a dividend in line with its industry peers.
With a yearly dividend of 0.36%, DHR is not a good candidate for dividend investing.
With a Dividend Yield of 0.36, DHR pays less dividend than the S&P500 average, which is at 2.41.
DHR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
VS Industry
Dividend Yield (0.36%) VS Industry: 57% outperformed.
0.20
0.72
DANAHER CORP263.79
NYSE:DHR (2/6/2023, 1:56:09 PM)-6.06 (-2.25%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Life Sciences Tools & Services | ||
| Earnings (Last) | 01-24 2023-01-24/bmo | Earnings (Next) | 04-19 2023-04-19/amc |
| Inst Owners | 77.19% | Inst Owner Change | -56.25% |
| Ins Owners | 0.47% | Ins Owner Change | 2.71% |
| Market Cap | 192.03B | Analysts | 80 |
| Price Target | 311.15 (17.95%) | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
| Dividend Growth(5Y) | 9.32% | DP | 11.52% |
| Div Incr Years | 5 | Div Non Decr Years | 5 |
| Ex-Date | N/A | ||
| EPS beat(2) | 2 | Avg EPS beat(2) | 11.9% |
| Min EPS beat(2) | 11.67% | Max EPS beat(2) | 12.13% |
| EPS beat(4) | 4 | Avg EPS beat(4) | 10.69% |
| Min EPS beat(4) | 2.64% | Max EPS beat(4) | 16.31% |
| Revenue beat(2) | 2 | Avg Revenue beat(2) | 5.41% |
| Min Revenue beat(2) | 4.84% | Max Revenue beat(2) | 5.99% |
| Revenue beat(4) | 4 | Avg Revenue beat(4) | 4.21% |
| Min Revenue beat(4) | 0.91% | Max Revenue beat(4) | 5.99% |
| PT rev (1m) | -0.39% | PT rev (3m) | -0.87% |
| EPS NQ rev (1m) | -8.24% | EPS NQ rev (3m) | -9.74% |
| EPS NY rev (1m) | 0% | EPS NY rev (3m) | -2.49% |
| Revenue NQ rev (1m) | -3.9% | Revenue NQ rev (3m) | -4.07% |
| Revenue NY rev (1m) | 0% | Revenue NY rev (3m) | -0.03% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.09 | ||
| Fwd PE | 25.03 | ||
| P/S | 6.1 | ||
| P/FCF | 26.07 | ||
| P/OCF | 22.54 | ||
| P/B | 3.83 | ||
| P/tB | N/A | ||
| EV/EBITDA | 19.26 |
| EPS(TTM) | 10.95 | EY | 4.15% |
| EPS(NY) | 10.54 | Fwd EY | 3.99% |
| FCF(TTM) | 10.12 | FCFY | 3.84% |
| OCF(TTM) | 11.7 | OCFY | 4.44% |
| SpS | 43.23 | BVpS | 68.8 |
| TBVpS | -13.7 | PEG (NY) | N/A |
| PEG (5Y) | 1.09 | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.42% | ||
| ROE | 14.18% | ||
| ROIC | 9.75% | ||
| ROICexc | 10.58% | ||
| ROICexgc | 74.7% | ||
| OM | 27.61% | ||
| PM | 22.57% | ||
| GM | 60.21% |
| ROICexgc(3y) | 70.02% | ROICexcg growth 3Y | 8.58% |
| ROICexcg growth 5Y | 8.54% | ROICexc(3y) | 8.37% |
| ROICexc growth 3Y | 12.25% | ROICexc growth 5Y | 14.76% |
| OM growth 3Y | 14.79% | OM growth 5Y | 10.74% |
| PM growth 3Y | 11.2% | PM growth 5Y | 7.05% |
| GM growth 3Y | 2.6% | GM growth 5Y | 1.74% |
| F-Score | 7 | Asset Turnover | 0.37 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | 2.67 | ||
| Debt/EBITDA | 1.8 | ||
| Cap/Depr | 51.85% | ||
| Profit Quality | 103.72% | ||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.52 | ||
| Altman-Z | 4.91 |
| F-Score | 7 | WACC | 9.73% |
| ROIC/WACC | 7.68 | Cap/Depr(3y) | 52.03% |
| Cap/Depr(5y) | 51.93% | Profit Quality(3y) | 123.58% |
| Profit Quality(5y) | 122.1% | ||
| EPS 1Y | 8.85% | EPS 3Y | 32.57% |
| EPS 5Y | 22.13% | EPS growth Q2Q | 6.69% |
| EPS Next Y | -3.77% | EPS Next 2Y | 2.85% |
| EPS Next 3Y | 5.28% | EPS Next 5Y | 8.6% |
| Revenue growth 1Y | 6.85% | Revenue growth 3Y | 20.67% |
| Revenue growth 5Y | 15.19% | Revenue growth Q2Q | 2.71% |
| Revenue Next Year | -0.07% | Revenue Next 2Y | 3.83% |
| Revenue Next 3Y | 5.18% | Revenue Next 5Y | 5.95% |
| EBIT growth 1Y | 16.38% | EBIT growth 3Y | 38.52% |
| EBIT growth 5Y | 27.56% | EBIT Next Year | 9.38% |
| EBIT Next 3Y | 8.98% | EBIT Next 5Y | 9.22% |
| FCF growth 1Y | 4.29% | FCF growth 3Y | 30.48% |
| FCF growth 5Y | 20.85% | OCF growth 1Y | 1.93% |
| OCF growth 3Y | 29.18% | OCF growth 5Y | 19.62% |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA